Vistagen Therapeutics, Inc. (VTGN) — 8-K Filings

8-K Filings (25)

• 8-K Filing — Dec 22, 2025
• Vistagen Therapeutics Files 8-K: Director/Officer Changes & More — Dec 3, 2025 Risk: medium
  Vistagen Therapeutics, Inc. filed an 8-K on December 3, 2025, reporting events as of November 28, 2025. The filing includes information regarding the departure
• Vistagen Therapeutics Files 8-K on Financials — Nov 13, 2025 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• 8-K Filing — Nov 4, 2025
• Vistagen Therapeutics Files 8-K on Officer/Director Changes — Oct 29, 2025 Risk: medium
  Vistagen Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appoin
• Vistagen Therapeutics Files 8-K on Officer/Director Changes — Sep 15, 2025 Risk: medium
  Vistagen Therapeutics, Inc. filed an 8-K on September 15, 2025, reporting on events that occurred on September 9, 2025. The filing includes information regardin
• Vistagen Therapeutics Files 8-K on Leadership Changes — Jun 25, 2025 Risk: medium
  Vistagen Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and comp
• Vistagen Therapeutics Files 8-K — Jun 2, 2025 Risk: low
  On June 2, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits.
• Vistagen Therapeutics Files 8-K — Mar 6, 2025 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on March 6, 2025, reporting on events that occurred on March 3, 2025. The filing primarily concerns financial statement
• Vistagen Therapeutics Files 8-K — Feb 5, 2025 Risk: low
  On February 5, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
• Vistagen Therapeutics Files 8-K — Jan 14, 2025 Risk: low
  On January 14, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
• Vistagen Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting an event that occurred on January 10, 2025. The filing pertains to 'Other Events' and 'F
• 8-K Filing — Dec 6, 2024
• Vistagen Therapeutics Files 8-K — Sep 23, 2024 Risk: low
  On September 23, 2024, Vistagen Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorpora
• Vistagen Therapeutics Files 8-K on Shareholder Vote Matters — Aug 28, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on August 28, 2024, reporting on matters submitted to a vote of security holders as of August 26, 2024. The filing deta
• Vistagen Therapeutics Files 8-K on Financials — Aug 13, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial state
• Vistagen Therapeutics Secures $100M Private Placement — Jul 12, 2024 Risk: medium
  Vistagen Therapeutics, Inc. announced on July 8, 2024, that it has entered into a securities purchase agreement for a private placement of approximately $100 mi
• Vistagen Therapeutics Files 8-K — Jul 10, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on July 10, 2024, reporting an event that occurred on July 9, 2024. The filing pertains to financial statements and exh
• Vistagen Therapeutics Files 8-K with Exhibits — Jun 28, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on June 28, 2024, reporting an event that occurred on June 27, 2024. The filing primarily concerns financial statements
• Vistagen Therapeutics Files 8-K on Shareholder Vote Matters — May 31, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The filing details th
• Vistagen Therapeutics Files 8-K — May 24, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on May 23, 2024, reporting other events and financial statements. The filing details the company's principal executive
• Vistagen Therapeutics Files 8-K — Apr 26, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on April 25, 2024, reporting other events and financial statements. The filing details the company's principal executiv
• Vistagen Therapeutics Files 8-K — Apr 1, 2024 Risk: low
  Vistagen Therapeutics, Inc. filed an 8-K on April 1, 2024, reporting other events and financial statements. The filing details the company's principal executive
• Vistagen Therapeutics Files 8-K, Confirms Nasdaq Listing — Jan 9, 2024
  Vistagen Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded com
• Vistagen Files 8-K on Dec 27 Event; Details Pending — Jan 3, 2024
  Vistagen Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 27, 2023. This filing, under 'Other Events' and 'Finan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX